ZYN’s Modified Risk Tobacco Product application has cleared the FDA’s scientific review phase, moving the brand closer to obtaining the modified risk marketing authorisation that would allow it to make explicit health claims in its advertising. The development is significant not just for ZYN and its parent company Philip Morris International, but for the entire nicotine pouch category — a positive MRTP outcome for the market leader would establish a regulatory template that other brands could follow and would substantially affect how the category is positioned to consumers.
An MRTP designation allows a manufacturer to communicate that their product presents reduced risk compared to cigarettes — a claim that is currently prohibited even where the evidence supports it. For nicotine pouches, this prohibition is particularly consequential because the relative risk reduction compared to combustible tobacco is among the largest available in the nicotine product space. Adult smokers making decisions about product switching would benefit from clear, FDA-validated communication about this risk differential.
The scientific review process examined ZYN’s evidence package on two dimensions: whether the product itself presents reduced risk to individual users, and whether authorising modified risk marketing would benefit the population as a whole — taking into account not just switching among current smokers but also the potential for the marketing to attract new nicotine users. This population-level assessment is what has made MRTP applications difficult and time-consuming; the FDA must weigh individual product risk against population-level exposure questions.
The fact that the application has cleared scientific review suggests the FDA’s reviewers found ZYN’s evidence package sufficiently robust to support a positive recommendation. The final decision involves additional regulatory and administrative steps, but the scientific clearance is the most significant hurdle in the process.
Competitors are watching carefully. VELO, On!, Rogue, and other brands with significant market positions have been developing their own evidence bases in anticipation of eventually pursuing MRTP designations. A ZYN approval would accelerate those timelines and raise the competitive stakes in a market that may soon have a clear regulatory framework for communicating relative risk to consumers.
